Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Roche Holding AG
  6. News
  7. Summary
    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
Delayed Swiss Exchange  -  11:31 2022-10-05 am EDT
328.00 CHF   -1.43%
08:27aAC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer's disease and Down syndrome
AQ
08:27aChugai Pharmaceutical Co., Ltd. - Relief Efforts Support for Season's Fifteenth Typhoon
AQ
08:09aROCHE HOLDINGS AG : Goldman Sachs gives a Buy rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Jemincare Announces Exclusive License Agreement with Genentech to Develop and Commercialize Novel Oral Androgen Receptor Degrader

08/18/2022 | 03:03am EDT

Jemincare announced that it and its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co. Ltd., have entered into an exclusive worldwide license agreement with Roche and Genentech, a member of the Roche Group, for the development and commercialization of its androgen receptor degrader, JMKX002992. Under the terms of the agreement, Genentech will be granted an exclusive license to develop and commercialize the degrader worldwide, and will be fully responsible for the development and commercialization costs.

In return, Genentech will pay Jemincare a USD 60 million upfront payment. Jemincare is also entitled to receive up to USD 590 million in additional payments upon achievement of certain development, regulatory and sales-based milestone targets. Jemincare is also entitled to receive tiered royalties on net sales.

JMKX002992 is a novel oral degrader of the androgen receptor, a confirmed disease driver in prostate cancer. JMKX002992 has the potential to treat patients with prostate cancer who have developed resistance to current therapies.


© S&P Capital IQ 2022
Stocks mentioned in the article
ChangeLast1st jan.
PAX DOLLAR (USDP/USD) 0.40% 0.999 End-of-day quote.-0.09%
ROCHE HOLDING AG -1.43% 328 Delayed Quote.-12.23%
All news about ROCHE HOLDING AG
08:27aAC Immune Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Al..
AQ
08:27aChugai Pharmaceutical Co., Ltd. - Relief Efforts Support for Season's Fifteenth Typhoon
AQ
08:09aROCHE HOLDINGS AG : Goldman Sachs gives a Buy rating
MD
01:00aRoche to present new data from its expanding neuromuscular disease portfolio at World M..
AQ
10/04Global Market Rally Pushes European Stocks Higher; Stoxx 600 Gains More Than 3%
MT
10/04ROCHE HOLDINGS AG : Deutsche Bank reiterates its Neutral rating
MD
10/04ROCHE HOLDINGS AG : JP Morgan remains Neutral
MD
10/04Switzerland's Roche Secures US FDA Nod for Breast Cancer Drug Enhertu's Companion Diagn..
MT
10/04Roche receives FDA approval for first companion diagnostic to identify patients with HE..
GL
10/03Roche names Sause head of diagnostics arm
RE
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Financials
Sales 2022 63 833 M 65 157 M 65 157 M
Net income 2022 14 661 M 14 965 M 14 965 M
Net Debt 2022 11 527 M 11 766 M 11 766 M
P/E ratio 2022 17,9x
Yield 2022 2,90%
Capitalization 270 B 274 B 275 B
EV / Sales 2022 4,41x
EV / Sales 2023 4,26x
Nbr of Employees 100 920
Free-Float 89,0%
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 332,75 CHF
Average target price 375,85 CHF
Spread / Average Target 13,0%
EPS Revisions
Managers and Directors
Severin Schwan Chief Executive Officer & Executive Director
Alan Hippe Chief Financial & Information Officer
Christoph Franz Chairman
Levi A. Garraway Chief Medical Officer
Pascale Schmidt Chief Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
ROCHE HOLDING AG-12.23%279 092
JOHNSON & JOHNSON-3.19%435 445
ELI LILLY AND COMPANY16.41%313 453
ABBVIE INC.4.87%251 052
PFIZER, INC.-24.71%249 525
NOVO NORDISK A/S6.91%238 512